V
Versantis
A Swiss pharmaceutical company developing new generations of liver disease medicines and diagnostics
About Versantis
Versantis is a biotechnology company focused on developing innovative therapeutics and diagnostics for liver diseases. The company primarily serves patients suffering from acute hepatic conditions, such as acute hepatic encephalopathy (HE), acute-on-chronic liver failure (ACLF), and urea cycle disorders (UCDs). Operating in the biopharmaceutical market, Versantis aims to address the high unmet medical needs associated with these severe liver conditions.
The company's lead product candidate, VS-01, is currently in Phase 1b clinical trials for the acute treatment of decompensated cirrhosis. VS-01 has received orphan drug designations from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), highlighting its potential to address critical liver deficiencies. Versantis' business model revolves around the research, development, and eventual commercialization of these life-saving therapies.
Revenue generation for Versantis is expected to come from the successful approval and commercialization of its drug candidates, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Zurich, Switzerland
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 58.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Health Diagnostics, Spinout, Metabolism, Liver, Biotech and Pharma, Woman Founder, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Sep 2022 | $37M | $60M | Genfit | ↗ |
| GRANT✓Other financing | Apr 2022 | $435K | — | Innosuisse | ↗ |
Growth signals
Latest recorded traffic for Versantis is 220 monthly website visits, down 38.9% over the last three months. Versantis's team declined 92.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Venture Kick
Innosuisse
Gebert Rüf Foundation
Series A9 investors entered at this stage
MassChallenge
Redalpine
HealthEquity
Altus Capital Partners
OCCIDENT
ZKB - Zürcher Kantonalbank
Swisscanto Invest
Verve Ventures
Esperante Ventures
Other known investors5 additional known investors
ETH Zurich
Genfit
MK Venture Capital
VentureLab
VentureOut
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Versantis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Versantis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.